nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—Tumour lysis syndrome—Fludarabine—lymphatic system cancer	0.0418	0.0437	CcSEcCtD
Carfilzomib—Peripheral motor neuropathy—Vincristine—lymphatic system cancer	0.0388	0.0406	CcSEcCtD
Carfilzomib—Lymphopenia—Mechlorethamine—lymphatic system cancer	0.035	0.0366	CcSEcCtD
Carfilzomib—Disease progression—Carmustine—lymphatic system cancer	0.034	0.0356	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Vincristine—lymphatic system cancer	0.0255	0.0267	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Mitoxantrone—lymphatic system cancer	0.0249	0.026	CcSEcCtD
Carfilzomib—Multi-organ failure—Vincristine—lymphatic system cancer	0.0218	0.0227	CcSEcCtD
Carfilzomib—Haemorrhage intracranial—Mitoxantrone—lymphatic system cancer	0.0168	0.0176	CcSEcCtD
Carfilzomib—Hypomagnesaemia—Bleomycin—lymphatic system cancer	0.0134	0.014	CcSEcCtD
Carfilzomib—Tumour lysis syndrome—Methotrexate—lymphatic system cancer	0.0124	0.013	CcSEcCtD
Carfilzomib—PSMB10—Vinblastine—Vincristine—lymphatic system cancer	0.0116	0.265	CbGdCrCtD
Carfilzomib—Sepsis—Teniposide—lymphatic system cancer	0.0115	0.012	CcSEcCtD
Carfilzomib—PSMB8—Podofilox—Teniposide—lymphatic system cancer	0.0108	0.247	CbGdCrCtD
Carfilzomib—Neuritis—Vincristine—lymphatic system cancer	0.0095	0.00993	CcSEcCtD
Carfilzomib—Hepatic failure—Fludarabine—lymphatic system cancer	0.00937	0.0098	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.00929	0.00971	CcSEcCtD
Carfilzomib—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00859	0.00898	CcSEcCtD
Carfilzomib—Neutropenia—Teniposide—lymphatic system cancer	0.00775	0.0081	CcSEcCtD
Carfilzomib—PSMB2—Azacitidine—Fludarabine—lymphatic system cancer	0.00762	0.175	CbGdCrCtD
Carfilzomib—Bacterial infection—Methotrexate—lymphatic system cancer	0.00745	0.00779	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.00724	0.00757	CcSEcCtD
Carfilzomib—PSMB2—Azacitidine—Cytarabine—lymphatic system cancer	0.0072	0.165	CbGdCrCtD
Carfilzomib—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00701	0.00733	CcSEcCtD
Carfilzomib—Neutropenia—Fludarabine—lymphatic system cancer	0.00681	0.00712	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00677	0.00707	CcSEcCtD
Carfilzomib—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00657	0.00687	CcSEcCtD
Carfilzomib—Pneumonia—Fludarabine—lymphatic system cancer	0.00653	0.00683	CcSEcCtD
Carfilzomib—Sepsis—Carmustine—lymphatic system cancer	0.00644	0.00674	CcSEcCtD
Carfilzomib—PSMB8—Vinorelbine—Vincristine—lymphatic system cancer	0.00641	0.147	CbGdCrCtD
Carfilzomib—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.0064	0.00669	CcSEcCtD
Carfilzomib—Renal failure—Fludarabine—lymphatic system cancer	0.00638	0.00667	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00636	0.00665	CcSEcCtD
Carfilzomib—Infection—Mechlorethamine—lymphatic system cancer	0.00635	0.00664	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00626	0.00654	CcSEcCtD
Carfilzomib—Anorexia—Mechlorethamine—lymphatic system cancer	0.00609	0.00637	CcSEcCtD
Carfilzomib—Sepsis—Mitoxantrone—lymphatic system cancer	0.00599	0.00626	CcSEcCtD
Carfilzomib—Chills—Teniposide—lymphatic system cancer	0.00595	0.00622	CcSEcCtD
Carfilzomib—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.0058	0.00606	CcSEcCtD
Carfilzomib—Hepatic failure—Vincristine—lymphatic system cancer	0.00573	0.00599	CcSEcCtD
Carfilzomib—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00555	0.00581	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00553	0.00578	CcSEcCtD
Carfilzomib—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00543	0.00568	CcSEcCtD
Carfilzomib—Hyponatraemia—Carmustine—lymphatic system cancer	0.00541	0.00566	CcSEcCtD
Carfilzomib—Anaemia—Teniposide—lymphatic system cancer	0.00533	0.00558	CcSEcCtD
Carfilzomib—Chills—Fludarabine—lymphatic system cancer	0.00523	0.00547	CcSEcCtD
Carfilzomib—Hyponatraemia—Vincristine—lymphatic system cancer	0.00517	0.0054	CcSEcCtD
Carfilzomib—Leukopenia—Teniposide—lymphatic system cancer	0.00517	0.0054	CcSEcCtD
Carfilzomib—Pain in extremity—Vincristine—lymphatic system cancer	0.00515	0.00538	CcSEcCtD
Carfilzomib—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00503	0.00526	CcSEcCtD
Carfilzomib—Hypertension—Teniposide—lymphatic system cancer	0.00498	0.00521	CcSEcCtD
Carfilzomib—Hypokalaemia—Carmustine—lymphatic system cancer	0.00491	0.00513	CcSEcCtD
Carfilzomib—Cardiac arrest—Vincristine—lymphatic system cancer	0.00489	0.00512	CcSEcCtD
Carfilzomib—Pneumonia—Bleomycin—lymphatic system cancer	0.00479	0.005	CcSEcCtD
Carfilzomib—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.0047	0.00491	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00469	0.00491	CcSEcCtD
Carfilzomib—Anaemia—Fludarabine—lymphatic system cancer	0.00469	0.0049	CcSEcCtD
Carfilzomib—Infection—Teniposide—lymphatic system cancer	0.00468	0.00489	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00463	0.00484	CcSEcCtD
Carfilzomib—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00461	0.00482	CcSEcCtD
Carfilzomib—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.00456	0.00477	CcSEcCtD
Carfilzomib—Leukopenia—Fludarabine—lymphatic system cancer	0.00454	0.00475	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00451	0.00472	CcSEcCtD
Carfilzomib—Anorexia—Teniposide—lymphatic system cancer	0.00449	0.00469	CcSEcCtD
Carfilzomib—Cough—Fludarabine—lymphatic system cancer	0.00443	0.00463	CcSEcCtD
Carfilzomib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00437	0.00457	CcSEcCtD
Carfilzomib—Neutropenia—Carmustine—lymphatic system cancer	0.00436	0.00456	CcSEcCtD
Carfilzomib—Arthralgia—Fludarabine—lymphatic system cancer	0.00432	0.00452	CcSEcCtD
Carfilzomib—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00425	0.00444	CcSEcCtD
Carfilzomib—Hyperglycaemia—Carmustine—lymphatic system cancer	0.0042	0.00439	CcSEcCtD
Carfilzomib—Dyspnoea—Teniposide—lymphatic system cancer	0.0042	0.00439	CcSEcCtD
Carfilzomib—Pneumonia—Carmustine—lymphatic system cancer	0.00418	0.00437	CcSEcCtD
Carfilzomib—Neutropenia—Vincristine—lymphatic system cancer	0.00416	0.00435	CcSEcCtD
Carfilzomib—Infection—Fludarabine—lymphatic system cancer	0.00411	0.0043	CcSEcCtD
Carfilzomib—Decreased appetite—Teniposide—lymphatic system cancer	0.00409	0.00428	CcSEcCtD
Carfilzomib—Renal failure—Carmustine—lymphatic system cancer	0.00408	0.00427	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00407	0.00426	CcSEcCtD
Carfilzomib—Vomiting—Mechlorethamine—lymphatic system cancer	0.00406	0.00425	CcSEcCtD
Carfilzomib—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00405	0.00424	CcSEcCtD
Carfilzomib—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00405	0.00423	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00403	0.00421	CcSEcCtD
Carfilzomib—Pneumonia—Vincristine—lymphatic system cancer	0.00399	0.00417	CcSEcCtD
Carfilzomib—Anorexia—Fludarabine—lymphatic system cancer	0.00395	0.00413	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00391	0.00409	CcSEcCtD
Carfilzomib—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00391	0.00409	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00389	0.00406	CcSEcCtD
Carfilzomib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00388	0.00406	CcSEcCtD
Carfilzomib—Chills—Bleomycin—lymphatic system cancer	0.00383	0.00401	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00381	0.00398	CcSEcCtD
Carfilzomib—Renal failure—Mitoxantrone—lymphatic system cancer	0.0038	0.00397	CcSEcCtD
Carfilzomib—Nausea—Mechlorethamine—lymphatic system cancer	0.0038	0.00397	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00377	0.00394	CcSEcCtD
Carfilzomib—Body temperature increased—Teniposide—lymphatic system cancer	0.00372	0.00389	CcSEcCtD
Carfilzomib—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00371	0.00388	CcSEcCtD
Carfilzomib—Dyspnoea—Fludarabine—lymphatic system cancer	0.00369	0.00386	CcSEcCtD
Carfilzomib—Oedema peripheral—Carmustine—lymphatic system cancer	0.00367	0.00384	CcSEcCtD
Carfilzomib—Decreased appetite—Fludarabine—lymphatic system cancer	0.0036	0.00376	CcSEcCtD
Carfilzomib—Fatigue—Fludarabine—lymphatic system cancer	0.00357	0.00373	CcSEcCtD
Carfilzomib—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00354	0.0037	CcSEcCtD
Carfilzomib—Pain—Fludarabine—lymphatic system cancer	0.00354	0.0037	CcSEcCtD
Carfilzomib—Constipation—Fludarabine—lymphatic system cancer	0.00354	0.0037	CcSEcCtD
Carfilzomib—Anaemia—Bleomycin—lymphatic system cancer	0.00344	0.00359	CcSEcCtD
Carfilzomib—Asthenia—Teniposide—lymphatic system cancer	0.00338	0.00353	CcSEcCtD
Carfilzomib—Leukopenia—Bleomycin—lymphatic system cancer	0.00333	0.00348	CcSEcCtD
Carfilzomib—Cardiac disorder—Vincristine—lymphatic system cancer	0.0033	0.00345	CcSEcCtD
Carfilzomib—Body temperature increased—Fludarabine—lymphatic system cancer	0.00327	0.00342	CcSEcCtD
Carfilzomib—Cough—Bleomycin—lymphatic system cancer	0.00325	0.00339	CcSEcCtD
Carfilzomib—Diarrhoea—Teniposide—lymphatic system cancer	0.00322	0.00337	CcSEcCtD
Carfilzomib—Back pain—Carmustine—lymphatic system cancer	0.00314	0.00328	CcSEcCtD
Carfilzomib—Chills—Mitoxantrone—lymphatic system cancer	0.00311	0.00325	CcSEcCtD
Carfilzomib—Infection—Bleomycin—lymphatic system cancer	0.00302	0.00315	CcSEcCtD
Carfilzomib—Anaemia—Carmustine—lymphatic system cancer	0.003	0.00314	CcSEcCtD
Carfilzomib—Back pain—Vincristine—lymphatic system cancer	0.003	0.00313	CcSEcCtD
Carfilzomib—Vomiting—Teniposide—lymphatic system cancer	0.00299	0.00313	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—lymphatic system cancer	0.00299	0.00312	CcSEcCtD
Carfilzomib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00297	0.00311	CcSEcCtD
Carfilzomib—Asthenia—Fludarabine—lymphatic system cancer	0.00297	0.00311	CcSEcCtD
Carfilzomib—Headache—Teniposide—lymphatic system cancer	0.00295	0.00309	CcSEcCtD
Carfilzomib—Back pain—Mitoxantrone—lymphatic system cancer	0.00292	0.00305	CcSEcCtD
Carfilzomib—Leukopenia—Carmustine—lymphatic system cancer	0.00291	0.00304	CcSEcCtD
Carfilzomib—Anorexia—Bleomycin—lymphatic system cancer	0.00289	0.00303	CcSEcCtD
Carfilzomib—Anaemia—Vincristine—lymphatic system cancer	0.00286	0.00299	CcSEcCtD
Carfilzomib—Diarrhoea—Fludarabine—lymphatic system cancer	0.00283	0.00296	CcSEcCtD
Carfilzomib—Hypertension—Carmustine—lymphatic system cancer	0.0028	0.00293	CcSEcCtD
Carfilzomib—Nausea—Teniposide—lymphatic system cancer	0.0028	0.00293	CcSEcCtD
Carfilzomib—Anaemia—Mitoxantrone—lymphatic system cancer	0.00279	0.00292	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—lymphatic system cancer	0.00278	0.0029	CcSEcCtD
Carfilzomib—Leukopenia—Vincristine—lymphatic system cancer	0.00277	0.0029	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00277	0.00289	CcSEcCtD
Carfilzomib—Dyspnoea—Bleomycin—lymphatic system cancer	0.00271	0.00283	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—lymphatic system cancer	0.0027	0.00283	CcSEcCtD
Carfilzomib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.0027	0.00282	CcSEcCtD
Carfilzomib—Hypertension—Vincristine—lymphatic system cancer	0.00268	0.0028	CcSEcCtD
Carfilzomib—Decreased appetite—Bleomycin—lymphatic system cancer	0.00264	0.00276	CcSEcCtD
Carfilzomib—Cough—Mitoxantrone—lymphatic system cancer	0.00263	0.00275	CcSEcCtD
Carfilzomib—Infection—Carmustine—lymphatic system cancer	0.00263	0.00275	CcSEcCtD
Carfilzomib—Vomiting—Fludarabine—lymphatic system cancer	0.00263	0.00275	CcSEcCtD
Carfilzomib—Hypertension—Mitoxantrone—lymphatic system cancer	0.00261	0.00272	CcSEcCtD
Carfilzomib—Pain—Bleomycin—lymphatic system cancer	0.0026	0.00271	CcSEcCtD
Carfilzomib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00259	0.00271	CcSEcCtD
Carfilzomib—Headache—Fludarabine—lymphatic system cancer	0.00259	0.00271	CcSEcCtD
Carfilzomib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00257	0.00269	CcSEcCtD
Carfilzomib—Anorexia—Carmustine—lymphatic system cancer	0.00253	0.00264	CcSEcCtD
Carfilzomib—Infection—Vincristine—lymphatic system cancer	0.00251	0.00263	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00248	0.00259	CcSEcCtD
Carfilzomib—Nausea—Fludarabine—lymphatic system cancer	0.00246	0.00257	CcSEcCtD
Carfilzomib—Infection—Mitoxantrone—lymphatic system cancer	0.00245	0.00256	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00241	0.00252	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00241	0.00252	CcSEcCtD
Carfilzomib—Anorexia—Vincristine—lymphatic system cancer	0.00241	0.00252	CcSEcCtD
Carfilzomib—Body temperature increased—Bleomycin—lymphatic system cancer	0.0024	0.00251	CcSEcCtD
Carfilzomib—Insomnia—Carmustine—lymphatic system cancer	0.0024	0.00251	CcSEcCtD
Carfilzomib—Dyspnoea—Carmustine—lymphatic system cancer	0.00236	0.00247	CcSEcCtD
Carfilzomib—Anorexia—Mitoxantrone—lymphatic system cancer	0.00235	0.00245	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.0023	0.00241	CcSEcCtD
Carfilzomib—Decreased appetite—Carmustine—lymphatic system cancer	0.0023	0.00241	CcSEcCtD
Carfilzomib—Insomnia—Vincristine—lymphatic system cancer	0.00229	0.00239	CcSEcCtD
Carfilzomib—Pain—Carmustine—lymphatic system cancer	0.00227	0.00237	CcSEcCtD
Carfilzomib—Constipation—Carmustine—lymphatic system cancer	0.00227	0.00237	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00224	0.00235	CcSEcCtD
Carfilzomib—Decreased appetite—Vincristine—lymphatic system cancer	0.0022	0.0023	CcSEcCtD
Carfilzomib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.0022	0.0023	CcSEcCtD
Carfilzomib—Fatigue—Vincristine—lymphatic system cancer	0.00218	0.00228	CcSEcCtD
Carfilzomib—Asthenia—Bleomycin—lymphatic system cancer	0.00218	0.00228	CcSEcCtD
Carfilzomib—Pain—Vincristine—lymphatic system cancer	0.00216	0.00226	CcSEcCtD
Carfilzomib—Constipation—Vincristine—lymphatic system cancer	0.00216	0.00226	CcSEcCtD
Carfilzomib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00214	0.00224	CcSEcCtD
Carfilzomib—Fatigue—Mitoxantrone—lymphatic system cancer	0.00212	0.00222	CcSEcCtD
Carfilzomib—Pain—Mitoxantrone—lymphatic system cancer	0.00211	0.0022	CcSEcCtD
Carfilzomib—Constipation—Mitoxantrone—lymphatic system cancer	0.00211	0.0022	CcSEcCtD
Carfilzomib—Body temperature increased—Carmustine—lymphatic system cancer	0.00209	0.00219	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—lymphatic system cancer	0.00202	0.00211	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00201	0.0021	CcSEcCtD
Carfilzomib—Body temperature increased—Vincristine—lymphatic system cancer	0.002	0.00209	CcSEcCtD
Carfilzomib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00195	0.00204	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—lymphatic system cancer	0.00194	0.00202	CcSEcCtD
Carfilzomib—Vomiting—Bleomycin—lymphatic system cancer	0.00193	0.00202	CcSEcCtD
Carfilzomib—Asthenia—Carmustine—lymphatic system cancer	0.0019	0.00199	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—lymphatic system cancer	0.00189	0.00198	CcSEcCtD
Carfilzomib—Asthenia—Vincristine—lymphatic system cancer	0.00181	0.0019	CcSEcCtD
Carfilzomib—Diarrhoea—Carmustine—lymphatic system cancer	0.00181	0.0019	CcSEcCtD
Carfilzomib—Nausea—Bleomycin—lymphatic system cancer	0.0018	0.00189	CcSEcCtD
Carfilzomib—Asthenia—Mitoxantrone—lymphatic system cancer	0.00177	0.00185	CcSEcCtD
Carfilzomib—Dizziness—Carmustine—lymphatic system cancer	0.00175	0.00183	CcSEcCtD
Carfilzomib—Diarrhoea—Vincristine—lymphatic system cancer	0.00173	0.00181	CcSEcCtD
Carfilzomib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00169	0.00176	CcSEcCtD
Carfilzomib—Vomiting—Carmustine—lymphatic system cancer	0.00168	0.00176	CcSEcCtD
Carfilzomib—Dizziness—Vincristine—lymphatic system cancer	0.00167	0.00175	CcSEcCtD
Carfilzomib—Headache—Carmustine—lymphatic system cancer	0.00166	0.00174	CcSEcCtD
Carfilzomib—Vomiting—Vincristine—lymphatic system cancer	0.00161	0.00168	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.0016	0.00168	CcSEcCtD
Carfilzomib—Headache—Vincristine—lymphatic system cancer	0.00158	0.00166	CcSEcCtD
Carfilzomib—Nausea—Carmustine—lymphatic system cancer	0.00157	0.00165	CcSEcCtD
Carfilzomib—Vomiting—Mitoxantrone—lymphatic system cancer	0.00157	0.00164	CcSEcCtD
Carfilzomib—Chills—Methotrexate—lymphatic system cancer	0.00155	0.00162	CcSEcCtD
Carfilzomib—Headache—Mitoxantrone—lymphatic system cancer	0.00154	0.00161	CcSEcCtD
Carfilzomib—Nausea—Vincristine—lymphatic system cancer	0.0015	0.00157	CcSEcCtD
Carfilzomib—Nausea—Mitoxantrone—lymphatic system cancer	0.00146	0.00153	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—lymphatic system cancer	0.00145	0.00152	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—lymphatic system cancer	0.00139	0.00145	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—lymphatic system cancer	0.00135	0.00141	CcSEcCtD
Carfilzomib—Cough—Methotrexate—lymphatic system cancer	0.00131	0.00137	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—lymphatic system cancer	0.00128	0.00134	CcSEcCtD
Carfilzomib—Infection—Methotrexate—lymphatic system cancer	0.00122	0.00127	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.0012	0.00126	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—lymphatic system cancer	0.00117	0.00122	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00112	0.00117	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—lymphatic system cancer	0.00111	0.00116	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—lymphatic system cancer	0.00109	0.00114	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—lymphatic system cancer	0.00107	0.00112	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—lymphatic system cancer	0.00106	0.00111	CcSEcCtD
Carfilzomib—Pain—Methotrexate—lymphatic system cancer	0.00105	0.0011	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—lymphatic system cancer	0.00097	0.00101	CcSEcCtD
Carfilzomib—Asthenia—Methotrexate—lymphatic system cancer	0.000881	0.000921	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—lymphatic system cancer	0.00084	0.000878	CcSEcCtD
Carfilzomib—Dizziness—Methotrexate—lymphatic system cancer	0.000812	0.000848	CcSEcCtD
Carfilzomib—Vomiting—Methotrexate—lymphatic system cancer	0.00078	0.000816	CcSEcCtD
Carfilzomib—Headache—Methotrexate—lymphatic system cancer	0.000769	0.000804	CcSEcCtD
Carfilzomib—Nausea—Methotrexate—lymphatic system cancer	0.000729	0.000762	CcSEcCtD
